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Introduction
Trisomy 13 syndrome or Patau syndrome is the third
most common autosomal chromosomal trisomy after
trisomy 21 and trisomy 18. Goldstein and Nielsen [1]
reported the incidence of trisomy 13 to be 0.053 per
1,000 live births. In a 13-year incidence study of chro-
mosomal abnormalities in Arhus, Denmark, Nielsen
and Wohlert [2] found three cases of trisomy 13
among 34,910 newborn children, or an incidence of
0.09 per 1,000 live births, while Wyllie et al [3] found
an incidence of 0.077 per 1,000 live births. In a litera-
ture survey, Benn and Hsu [4] found three cases of tri-
somy 13 among 68,159 live births, or an incidence of
0.04 per 1,000. Prenatal ultrasound is a powerful tool
for the detection of structural abnormalities in trisomy
13 fetuses. The Table summarizes these structural
abnormalities, the markers or subtle findings, and the
placental abnormalities that may present on ultra-
sound throughout such pregnancies [5]. The placental
abnormalities encountered in trisomy 13 pregnancies
include reduced placental vascularization and smaller
placental volume in the first trimester, and a partial
molar appearance and placental mesenchymal dyspla-
sia in the second trimester [6]. To date, at least six stud-
ies of fetuses with trisomy 13 have been reported
[7–12]. This article provides a comprehensive review of
sonographic screening for structural abnormalities in
trisomy 13 fetuses during the first trimester and the
subtle sonographic findings in the second trimester.
Sonographic Screening for Structural
Abnormalities Associated with Trisomy 13
in the First Trimester
Papageorghiou et al [13] found that 92 of 181
(50.8%) trisomy 13 fetuses who underwent ultrasound
examination during the first trimester had omphalocele,
holoprosencephaly (HPE) and/or megacystis. Watson
et al [12] found that six of eight fetuses with trisomy
13 identified at 10–13 weeks of gestation had abnormal
sonographic findings, including cystic hygroma in four
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cases, HPE in one case and irregularly large yolk sac in
one case. Bronshtein et al [14] suggested that detailed
first-trimester ultrasound examination of fetuses with
abnormal nuchal translucency (NT) could shorten the
parental decision-making process and spare parents a
prolonged period of diagnostic uncertainty and anxiety,
particularly when a structural anomaly was clearly
diagnosed. In a study of 23 first-trimester fetuses with
increased NT thickness ≥ 3.5 mm, Bronshtein et al [14]
found severe anomalies in eight, mild anomalies in six,
trisomy 13 in two, and trisomy 21 in one. In their study,
one trisomy 13 fetus with NT thickness of 5.2 mm at
11+4 weeks of gestation had cleft lip and palate, congen-
ital diaphragmatic hernia, HPE, hypoplastic left heart,
micrognathia, and truncus arteriosus. Another trisomy
13 fetus had NT thickness of 6.0 mm at 12 weeks of
gestation, and had cleft lip and palate, HPE and pro-
boscis, while one trisomy 21 fetus with NT thickness of
4.4 mm at 13+3 weeks of gestation had hydronephrosis.
Omphalocele
Papageorghiou et al [13] found omphalocele in 28.2%
(51/181) of trisomy 13 fetuses in the first trimester.
Frequencies of omphalocele in trisomy 13 fetuses in the
second and third trimesters of 3.6% (1/28) [11],
11.1% (2/18) [15], 13.3% (2/15) [10], 15.2% (5/33)
[8], 22.6% (7/31) [7] and 29.4% (5/17) [16] have been
reported. Chromosomal abnormalities have been
reported in 10–12% of neonates with omphalocele and
in 30% of fetuses with omphalocele [17–22]. When the
diagnosis is made in early pregnancy, the incidence of
aneuploidy can increase to 61.1% (11/18) at 12–16
weeks of gestation [23] and 66.7% (12/18) at 11–14
weeks of gestation [20]. The chromosomal abnormali-
ties in 11 fetal omphaloceles reported by Blazer et al [23]
were trisomy 18 (n = 5), trisomy 21 (n = 2), triploidy
(n =2), trisomy 13 (n =1) and 45,X (n =1). The reported
chromosomal abnormalities in the 12 fetal omphalo-
celes reported by Snijders et al [20] were trisomy 18
(n = 10), trisomy 13 (n = 1) and triploidy (n = 1). In a
meta-analysis of chromosomal abnormalities associ-
ated with omphalocele, Chen [24] found that 36.2%
(415/1,148) of fetuses with prenatally detected om-
phalocele had chromosomal abnormalities, including
trisomy 18 in 66.7% (277/415), trisomy 13 in 17.3%
(72/415) and trisomy 21 in 6.3% (26/415).
Holoprosencephaly
Papageorghiou et al [13] found HPE in 26.5% (48/181)
of trisomy 13 fetuses in the first trimester. Frequencies of
Table. Prenatal ultrasound features of trisomy 13
Fetus
• Structural abnormalities
— First trimester: holoprosencephaly, omphalocele, megacystis, and congenital heart defects
— Second and third trimesters:
Brain: holoprosencephaly, brachycephaly, microcephaly, Dandy-Walker complex, posterior fossa abnormalities, 
ventriculomegaly, and spina bifida
Face: cyclopia, ethmocephaly, cebocephaly, premaxillary agenesis, cleft lip/palate, micrognathia, 
and hypoplastic nasal bone
Neck: cystic hygroma and nuchal edema
Heart: ventricular septal defects, atrial septal defects, patent ductus arteriosus, double-outlet right ventricle, 
hypoplastic left ventricle, mitral or aortic atresia, pulmonary stenosis, and anomalous venous return
Chest: diaphragmatic hernia
Abdominal wall: omphalocele
Urinary tract: renal cystic dysplasia, multicystic kidneys, enlarged and echogenic kidneys, 
hydronephrosis, and ureteral obstruction and duplication
Limbs: postaxial polydactyly of the hands and feet, clenched or overlapping digits, prominent calcaneus, 
and rocker-bottom feet
• Markers or subtle findings
— First trimester: increased nuchal translucency thickness, fetal tachycardia, absent nasal bone, abnormal ductus 
venosus flow, smaller crown-rump length, smaller trunk and head volume, increased frontomaxillary facial 
angle in the presence of holoprosencephaly, and smaller gestational sac volume
— Second trimester: echogenic intracardiac foci, echogenic bowel, pyelectasis, single umbilical artery, 
choroid plexus cysts, mild ventriculomegaly, and intrauterine growth restriction
Placenta
— First trimester: reduced placental vascularization and smaller placental volume
— Second trimester: partial molar appearance and placental mesenchymal dysplasia
16.7% (3/18) [15], 17.9% (5/28) [11], 35.5% (11/31)
[7], 39.4% (13/33) [8] and 46.7% (7/15) [10] have been
reported for HPE in trisomy 13 fetuses in the second and
third trimesters. Blaas et al [25] found chromosomal
abnormalities in 36.7% (11/30) of fetuses with prenatally
detected HPE, and trisomy 13 in 45.5% (5/11). Reported
frequencies of chromosomal abnormalities in fetuses
with HPE in other studies have included 28.9% (11/38)
[26], 33.3% (4/12) [27], 34.0% (17/50) [28], 38.8%
(100/258) [29], 41.3% (50/121) [30], 42.9% (6/14) [31]
and 57.6% (34/59) [32]. In a meta-analysis of chromoso-
mal abnormalities associated with HPE, Blaas et al
[25] suggested that the frequency was 34.7% (92/265)
or more. Using modern, high-frequency transvaginal
transducers, HPE can be diagnosed in the first tri-
mester [33–48]. Sepulveda et al [41] suggested that fail-
ure to identify the “butterfly” sign (a cross-sectional view
of the fetal brain, including visualization of both choroid
plexuses) was a warning sign for HPE in the first trimes-
ter. Kim et al [44] and Timor-Tritsch et al [45] success-
fully used three-dimensional inversion-rendering mode to
evaluate early fetal ventricles in HPE in the first trimester.
Megacystis
Papageorghiou et al [13] found megacystis in 11.6%
(21/181) of trisomy 13 fetuses in the first trimester. Fetal
megacystis at 10–14 weeks of gestation is defined by a
longitudinal bladder diameter of ≥7 mm [49,50]. Sebire
et al [49] detected fetal megacystis in 15 of 24,492
(1/1,633) pregnancies and chromosomal abnormalities
in three of the 15 cases (20%). These included trisomy
18 (n = 1), trisomy 13 (n = 1) and unbalanced translo-
cation involving chromosomes 14 and 20 (n = 1). They
also found that in the majority of chromosomally nor-
mal fetuses with mild or moderate enlargement of the
bladder (longitudinal bladder diameter, 8–12 mm),
there was spontaneous resolution by 20 weeks of ges-
tation with no obvious adverse effects. They also found
progressive obstructive uropathy in all fetuses with severe
megacystis (longitudinal bladder diameter, ≥ 17 mm).
Favre et al [51] reported chromosomal abnormalities
in four of 15 fetuses (26.7%) at 11–15 weeks of gesta-
tion, including trisomy 13 (n =2), trisomy 18 (n =1) and
trisomy 21 (n = 1). Liao et al [50] found that 30 of 
145 fetuses (20.7%) with megacystis at 10–14 weeks of 
gestation had chromosomal abnormalities, including tri-
somy 13 (n = 17), trisomy 18 (n = 7), trisomy 21 (n = 2),
triploidy (n = 1), trisomy 4 (n = 1), mosaic trisomy 15
(n = 1), and unbalanced translocation involving chro-
mosomes 14 and 20 (n =1). They also expected a signif-
icantly higher number of aneuploid fetuses with trisomy
13 and trisomy 18, but not trisomy 21 in cases of
megacystis. Liao et al [50] demonstrated that in fetuses
with megacystis and a longitudinal bladder diameter of
7–15 mm, the risk of aneuploidy was 23.6% (26/110),
compared with a risk of 11.4% (4/35) in those with a
longitudinal bladder diameter of > 15 mm. Liao et al
[50] additionally found that increased NT thickness was
present in about 75% of aneuploid and about 30% of
euploid fetuses with megacystis. About 90% of euploid
fetuses with a longitudinal bladder diameter of 7–15 mm
had spontaneous resolution, but all fetuses with a lon-
gitudinal bladder diameter > 15 mm had progressive
obstructive uropathy. Boissier et al [52] reported that
three of 12 (25%) fetuses with fetal megacystis in the
first trimester had chromosomal abnormalities, includ-
ing trisomy 18 (n = 2) and trisomy 21 (n = 1). Sepulveda
[53] concluded that early detection of megacystis
should include karyotyping and follow-up scans, and
that vesicocentesis should be managed promptly in
cases with progressive enlargement of the fetal blad-
der, while serial vesicocentesis with vesicoamniotic
shunting or cystoscopic procedures should be offered
as an alternative to termination of pregnancy, if the
condition did not resolve.
Congenital heart defects (CHD)
CHD have been found in more than 80% of fetuses
with trisomy 13 [54,55]. The commonest CHDs in tri-
somy 13 fetuses include ventricular septal defects, atrial
septal defects, patent ductus arteriosus, overriding
aorta, dextroposition, hypoplastic aorta, atretic mitral
and/or aortic valves, pulmonary stenosis, and anom-
alous pulmonary venous return [55]. Frequencies of
CHD in trisomy 13 fetuses in the second and third
trimesters have been reported as 33.3% (5/15) [42],
45.2% (14/31) [7], 48.5% (16/33) [8], 50.0% (9/18)
[15], 53.6% (15/28) [11], and 70.6% (12/17) [16].
Becker and Wegner [56] found that the overall detec-
tion rate for major CHD on the 11–13+6-week scan was
84.2% (32/38), with 37.5% (3/8) for NT < 2.5 mm and
96.7% (29/30) for NT ≥ 2.5 mm. In a study of pregnan-
cies with risk factors for fetal CHD, such as NT ≥ 4 mm,
a first-degree relative with CHD, or suspicion of CHD
or extracardiac abnormality on the 10–14-week scan,
Huggon et al [57] found chromosomal abnormalities
in 31.5% (70/222) of fetuses with a normal heart on
echocardiography (trisomy 21 [n = 47], trisomy 18
[n = 9], trisomy 13 [n = 4], 45,X [n = 3], and others
[n = 7]). In contrast, chromosomal abnormalities were
present  in 69.2% (18/26) of fetuses with atrioventricu-
lar septal defect (trisomy 21 [n =14], trisomy 18 [n =1],
trisomy 13 [n = 2], and others [n = 1]), in 71.4% (5/7)
of fetuses with hypoplastic left heart syndrome (trisomy
18 [n = 1] and 45,X [n = 4]), in 80.0% (8/10) of fetuses
with ventricular septal defect (trisomy 21 [n=2], trisomy
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18 [n = 5], and trisomy 13 [n = 1]), in 92.6% (25/27) of
fetuses with disproportion (trisomy 21 [n = 3], trisomy
18 [n = 5], trisomy 13 [n = 4], and 45,X [n = 13]), and
in 94.7% (18/19) of fetuses with isolated tricuspid valve
regurgitation (trisomy 21 [n = 14], trisomy 18 [n = 2],
45,X [n =1], and others [n =1]). In the study by Huggon
et al [57], seven of the 11 trisomy 13 fetuses (63.6%) had
confirmed cardiac abnormalities on echocardiography.
Echogenic Intracardiac Focus (EIF)
EIF is the subjective sonographic finding of an echogenic
spot over the capillary muscle, and its detection depends
on the resolution of the ultrasound equipment, the
operator’s experience, and the fetal position. EIF is a
common sonographic finding in the second trimester
and is observed in 3–4% of normal fetuses [58,59].
Roberts and Genest [60] reported that mineralization
of the cardiac papillary muscle was observed in 15.9%
(20/126) of fetuses with trisomy 21 and 39.1% (9/23)
of fetuses with trisomy 13, compared with only 2% of
normal fetuses. Lehman et al [8] reported that EIF was
found in 38.9% (7/18) of fetuses with trisomy 13 at
12–20 weeks of gestation, and Bromley et al [61] found
EIF in 18.2% (4/22) of fetuses with trisomy 21, com-
pared with 4.7% (62/1,312) of normal fetuses. However,
racial differences exist in the frequency of sonographi-
cally identified EIF in second-trimester fetal hearts [62].
Shipp et al [62] found incidences of EIF of 30.4%, 5.9%,
10.5% and 11.1% for Asian, black, white and unknown
women, suggesting that EIF is a normal condition that
occurs in about one-third of fetuses of Asian women.
Frequencies of 3.7% (2/54) [12], 14.3% (4/28) [11],
20% (3/15) [10] and 30.3% (10/33) [8] have been
reported in fetuses with trisomy 13.
Echogenic Bowel
Papp et al [11] found echogenic bowel in 17.9% (5/28)
of fetuses with trisomy 13. This condition occurs in
approximately 1 per 200 mid-trimester fetuses [63,64].
It may be a normal condition during the second trimester,
but has also been associated with intra-amniotic hem-
orrhage, severe uteroplacental insufficiency, cystic fibro-
sis, chromosomal abnormalities, and in utero infection
with cytomegalovirus and toxoplasmosis [63,65]. In a
study of karyotyped fetuses with echogenic bowel, after
exclusion of fetuses with major anomalies, Al-Kouatly
et al [65] found that 3.7% (5/136) had chromosomal
abnormalities, including trisomy 21 (n = 4) and trisomy
18 (n = 1). Bromley et al [66] reported that echogenic
bowel was found in 12.5% (6/48) of fetuses with tri-
somy 21, and that the risk of trisomy 21 in fetuses 
with isolated echogenic bowel was 1.4% (71/5,105).
Echogenic bowel is associated with a six- to seven-fold
increase in the risk of Down syndrome, or a risk in the
range of 1–2% [67,68]. In a study of 50 fetuses with
echogenic bowel, Bromley et al [66] found that 16%
(8/50) of fetuses had chromosomal abnormalities,
including trisomy 21 (n = 6), trisomy 13 (n = 1) and
Turner syndrome (n = 1), and that all aneuploid cases
had additional anomalies. Snijders et al [63] observed
that echogenic bowel was most commonly associated
with placental insufficiency and intrauterine growth
restriction (IUGR). In their study of 250 fetuses with
echogenic bowel, the frequencies of chromosomal
abnormalities in fetuses with IUGR, minor abnormali-
ties and major abnormalities were 0% (0/91), 2.5%
(3/122) (trisomy 21 [n = 1], trisomy 18 [n = 1], and
triploidy [n = 1]), and 35.8% (24/67) (trisomy 21
[n = 6], trisomy 18 [n = 6], trisomy 13 [n = 6], triploidy
[n = 2] and other rearrangements [n = 4]), respectively.
Single Umbilical Artery (SUA)
SUA has been found in 0.2–1.9% of deliveries [69–73].
Granese et al [74] reported a prevalence of 0.48%
(61/12,672) for SUA on prenatal ultrasound at 16–23
weeks of gestation. SUA can be associated with con-
genital malformations of all major organ systems and
with chromosomal abnormalities [75–80]. Prucka et al
[81] reported that SUA existed in 2% (97/4,846) of
pathologic specimens and that fetuses with SUA had
significantly more chromosomal abnormalities (10.3%
vs. 1.0%) and other congenital anomalies (27% vs. 8%).
Martínez-Frías et al [82] found that the most commonly
associated malformations were bilateral renal agenesis
and imperforate anus, followed by unilateral renal
agenesis and vertebral defects. SUA has been found in
more than 50% of fetuses with trisomy 18 and 10–50%
of fetuses with trisomy 13 [67].
In the first trimester, visualization of the umbilical
arteries on either side of the bladder and continuous
with the umbilical cord insertion to the fetus can be
obtained by color flow mapping in an oblique, trans-
verse section of the fetal abdomen including the umbili-
cus and the fetal bladder [83]. In a study of 717 fetuses
immediately before chorionic villus sampling at 11–14
weeks of gestation, Rembouskos et al [83] found SUA
in 3.3% (21/634) of fetuses with a normal karyotype,
11.4% (5/44) with trisomy 21, 77.8% (14/18) with tri-
somy 18 and 9.5% (2/21) with other chromosomal
abnormalities. The authors also found that at 11–14
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weeks of gestation, the most commonly associated
major structural defects were omphalocele and mega-
cystis, and the most common chromosomal abnor-
mality was trisomy 18 in fetuses with SUA.
In a meta-analysis of 936 fetuses with SUA diag-
nosed in the second and third trimesters, Rembouskos
et al [83] found that 79 fetuses (8.4%) had chromoso-
mal abnormalities, including trisomy 18 (n = 33), tri-
somy 13 (n=15), trisomy 21 (n=5), triploidy (n= 9) and
other rearrangements (n =17). In a study of fetuses with
SUA diagnosed in the second trimester, Lubusky et al
[84] found SUA in 4.8% (102/2,147) of cases, includ-
ing 12.8% (5/39) with trisomy 21, 50% (8/16) with tri-
somy 18, 25% (1/4) with trisomy 13 and 7.25% (5/69)
with other rearrangements. SUA has been reported to
occur in 9.3% (5/54) [12], 13.3% (2/15) [10] and 24.2%
(8/33) [8] of fetuses with trisomy 13.
Choroid Plexus Cysts
Choroid plexus cysts (CPCs) occur in approximately
1% of karyotypically normal fetuses and about 50% of
fetuses with trisomy 18 [85]. The reported frequency of
CPCs in the normal population ranges from 0.3% to
3.6% [86–89]. CPCs are a normal condition during the
second trimester and resolve by 26–28 weeks of gesta-
tion in more than 90% of cases, with no known patho-
logic association [63]. Sullivan et al [90] suggested that
normal results of maternal serum biochemical tests
and an absence of additional fetal anomalies on prena-
tal ultrasound could reliably exclude any underlying
chromosomal abnormality. In a meta-analysis of 1,806
fetuses with CPCs, Snijders et al [63] reported a mean
frequency of chromosomal abnormalities of 8%, includ-
ing trisomy 18 (n = 121), trisomy 21 (n = 18) and other
rearrangements (n = 11), with a frequency of 1% for
cases with isolated CPCs and 46% for those with mul-
tiple anomalies. They also found CPCs in 47% of fetuses
with trisomy 18 (n = 137), 8% with trisomy 21 (n = 155)
and 2% with trisomy 13 (n = 54). Yoder et al [91] found
a likelihood ratio of 13.8 (95% confidence interval, CI,
7.72–25.14; p < 0.001) for trisomy 18 and 1.87 (95% CI,
0.78–4.46; p = 0.16) for trisomy 21 in second-trimester
fetuses with isolated CPCs. Frequencies of 3.2% (1/31)
[7], 6.7% (1/15) [10] and 10.7% (3/28) [11] have
been reported for CPCs in fetuses with trisomy 13.
IUGR
The frequency of chromosomal abnormalities in
neonates with small gestational age is < 10% [92–95].
However, early IUGR is a common prenatal feature of
major chromosomal abnormalities, particularly trip-
loidy, trisomy 18 and trisomy 13 [95]. In a study of 458
fetuses with IUGR at 17–39 weeks of gestation, Snijders
et al [95] found chromosomal abnormalities in 19.4%
(89/458) of cases, including triploidy (n = 36), trisomy
18 (n=32), trisomy 21 (n=8), trisomy 13 (n=5), trisomy
22 (n=1) and other autosomal deletions or duplications
(n = 7). The frequency of chromosomal abnormalities
varied with gestational age at presentation (38% at
18–25 weeks, 10% at 26–33 weeks, and 15% at 34–41
weeks), the presence of fetal anomalies (40% with fetal
anomalies and 3% without fetal anomalies), amniotic
fluid volume (95% with increased volume, 32% with
normal volume, 10% with reduced volume, and 5%
with absent volume), and Doppler findings (44% with
absence of notch [–NT] and presence of end-diastolic
frequencies [+ EDF], 24% with –NT/–EDF, 12% with +
NT/+ EDF, and 8% with + NT/–EDF).
Triploid fetuses have early-onset asymmetrical IUGR
with macrocephaly and increased head-to-abdominal
circumference ratio, whereas fetuses with trisomy 18 and
trisomy 13 have symmetrical IUGR before 30 weeks’ ges-
tation [63]. Dicke and Crane [96] found that mid-
trimester IUGR was evident in 43% of fetuses with trisomy
13 (n = 9) and 59% of fetuses with trisomy 18 (n = 22),
but not in fetuses with trisomy 21 (n =43). Snijders et al
[63] found small gestational age in 100% of fetuses with
triploidy (n = 50), 74% with trisomy 18 (n = 137), 61%
with trisomy 13 (n = 54), 55% with Turner syndrome
(n=54), and 20% with trisomy 21 (n=155). Jauniaux et al
[97] reported that 62.5% (10/16) of fetuses with triploidy
had fetal crown-rump length below the fifth centile at
10–14 weeks of gestation. Bahado-Singh et al [98] re-
ported that, in the first trimester, fetuses with trisomy
18 and trisomy 13 were growth restricted, with significant
shortening of crown-rump length, but that fetuses with
trisomy 21 were not associated with early-onset IUGR.
Frequencies of 26.7% (4/15) [10], 48.4% (15/31)
[7] and 48.5% (16/33) [8] have been reported for
IUGR in fetuses with trisomy 13.
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